SCHEMBL5192872

SCHEMBL5192872

CCC(CC)n1cnc2c(NCc3ccccc3)nc(Cl)nc21

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 17/20 0.79
KDM4E B2RXH2 1/20 0.61
NPC1 O15118 1/20 0.61
MAPT P10636 1/20 0.61
TDP1 Q9NUW8 1/20 0.61
CDK5 Q00535 6/20 0.60
CDK2 P24941 13/20 0.55
CDK7 P50613 10/20 0.55
CCNE1 P24864 9/20 0.55
CCNB1 P14635 9/20 0.55
CDK4 P11802 7/20 0.55
CCND1 P24385 7/20 0.55
CCNH P51946 7/20 0.55
CDK9 P50750 4/20 0.55
MAPK1 P28482 4/20 0.55
CSNK1D P48730 3/20 0.55
CLK2 P49760 3/20 0.55
DYRK1A Q13627 3/20 0.55
CLK4 Q9HAZ1 3/20 0.55
CSNK1G2 P78368 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5196875 0.91 CDK1 (0.83) CDK1KDM4ENPC1MAPTTDP1
SCHEMBL1400442 0.88 CDK1 (1.00) CDK1KDM4ENPC1MAPTTDP1
SCHEMBL5193584 0.87 CDK1 (0.61) CDK1
SCHEMBL1355796 0.84 CDK1 (0.57) CDK1CDK5CDK2CDK7CCNE1
SCHEMBL21450119 0.84 CDK1 (0.79) CDK1KDM4ENPC1MAPTTDP1
SCHEMBL5193482 0.83 CDK5 (0.60) CDK1NPC1CDK5CDK2CCNE1
SCHEMBL20350685 0.82 CDK1 (0.73) CDK1KDM4ENPC1MAPTTDP1
SCHEMBL17628615 0.82 CDK1 (0.87) CDK1KDM4ENPC1MAPTTDP1
SCHEMBL5196618 0.82 CDK1 (0.52) CDK1CDK5CDK2CCNB1DYRK1A
SCHEMBL8010398 0.82 CDK1 (1.00) CDK1KDM4EMAPTTDP1CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1183256-B1 PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AVENTIS PHARMA SA (FR) 2007-08-22 EP disclosed
US-7208598-B2 Derivatives of purine, their preparation process and pharmaceutical compositions containing them AVENTIS PHARMA (FR) 2007-04-24 US disclosed
US-7122669-B1 Purine derivatives, preparation method and pharmaceutical compositions containing same HOECHST MARION ROUSSEL (FR) 2006-10-17 US disclosed
US-20050187228-A1 Derivatives of purine, their preparation process and pharmaceutical compositions containing them AVENTIS PHARMA S.A. 2005-08-25 US disclosed
EP-1183256-A1 PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Aventis Pharma S.A. (FR) 2002-03-06 EP disclosed
WO-2000071543-A1 PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AVENTIS PHARMA S.A. (FR) 2000-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187228-A1 Derivatives of purine, their preparation process and pharmaceutical compositions containing them CDK6, CDK1, CDK2 CDK1 2/4885KDM4E 470/4885NPC1 3546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.